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Abstract
The purpose of this study was to develop novel liquid crystalline nanoparticles (LCNPs) that display improved pre-ocular
residence time and ocular bioavailability and that can be used as an ophthalmic delivery system for tetrandrine (TET).
The delivery system consisted of three primary components, including glyceryl monoolein, poloxamer 407, and water,
and two secondary components, including Gelucire 44/14 and amphipathic octadecyl-quaternized carboxymethyl
chitosan. The amount of TET, the amount of glyceryl monoolein, and the ratio of poloxamer 407 to glyceryl monoolein
were selected as the factors that were used to optimize the dependent variables, which included encapsulation
efficiency and drug loading. A three-factor, five-level central composite design was constructed to optimize the
formulation. TET-loaded LCNPs (TET-LCNPs) were characterized to determine their particle size, zeta potential,
entrapment efficiency, drug loading capacity, particle morphology, inner crystalline structure, and in vitro drug
release profile. Corneal permeation in excised rabbit corneas was evaluated. Pre-ocular retention was determined
using a noninvasive fluorescence imaging system. Finally, pharmacokinetic study in the aqueous humor was
performed by microdialysis technique. The optimal formulation had a mean particle size of 170.0 ± 13.34 nm, a
homogeneous distribution with polydispersity index of 0.166 ± 0.02, a positive surface charge with a zeta potential of
29.3 ± 1.25 mV, a high entrapment efficiency of 95.46 ± 4.13 %, and a drug loading rate of 1.63 ± 0.07 %. Transmission
electron microscopy showed spherical particles that had smooth surfaces. Small-angle X-ray scattering profiles revealed
an inverted hexagonal phase. The in vitro release assays showed a sustained drug release profile. A corneal permeation
study showed that the apparent permeability coefficient of the optimal formulation was 2.03-fold higher than that of
the TET solution. Pre-ocular retention capacity study indicated that the retention of LCNPs was significantly longer than
that of the solution (p < 0.01). In addition, a pharmacokinetic study of rabbit aqueous humors demonstrated that the
TET-LCNPs showed 2.65-fold higher ocular bioavailability than that of TET solution. In conclusion, a LCNP system could
be a promising method for increasing the ocular bioavailability of TET by enhancing its retention time and permeation
into the cornea.
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Background
Among ocular drug delivery systems, the topical application
of drug solutions in eye drops is the most common and
accepted method of treating ocular diseases. However,
solutions contained in drops typically display poor corneal
penetration and have short pre-ocular retention times. To
overcome these shortcomings, emulsions, liposomes, nano-
particles, microspheres, nanocapsules, and micelles are be-
ing developed as new ophthalmic delivery systems [1–6].
These systems can enhance ocular drug bioavailability by
promoting transcorneal penetration, but as with traditional
eye drops, the same rapid rates of drainage that result in
the rapid pre-corneal loss of the drug and consequently low
bioavailability have been observed in these formulations.
Liquid crystalline nanoparticles (LCNPs) are formed
by some amphiphilic lipids in the presence of excess
water, and they have therefore been proposed as po-
tential drug delivery vehicles [7]. LCNPs offer higher
encapsulation than other drug delivery systems be-
cause they have a higher proportion of lipids in the
particle and therefore present a larger surface area.
Moreover, previous research studies have revealed that
LCNPs can incorporate large amounts of drugs with
varying physicochemical properties. Taking into ac-
count the bioadhesive nature, nontoxicity, and
sustained-release behavior, LCNPs show great promise
as vehicles for the ocular administration of drugs.
Furthermore, research of LCNPs as a drug delivery
system has involved oral, percutaneous, and intraven-
ous routes of administration [8–10].
The lipid that is most widely used to construct LCNP
systems is glyceryl monooleate (GMO), which displays a
biofilm-like microstructure that enables the lipid bilayer of
GMO to fuse with epithelial cells. Furthermore, GMO, as
a nontoxic, biodegradable, and biocompatible material, has
demonstrated great potential for use in pharmaceutical
applications. It spontaneously forms a well-ordered li-
quid crystal phase in water. According to differences in
their internal structures, the liquid crystalline phases of
these formulations include a lamellar phase (Lа), an
inverted hexagonal phase (H2), and a cubic phase (V2)
[11–13]. Among these phases, the non-lamellar phase
is the most extensively studied phase in pharmaceutical
research [14].
TET, (1β)-6,6′,7,12-tetramethoxy-2,2'-dimethylberba-
man(S, S)-(+)-tetrandrine, is an alkaloid that is extracted
from the Chinese medicinal herb Radix Stephania tetra-
ndra S. that has been used clinically to treat chronic
keratitis, cataracts, retinopathy, and glaucoma [15–17].
Unfortunately, although TET has many pharmacological
effects, its therapeutic efficacy is greatly limited because
of its low aqueous solubility.
Thus, it is desirable to design a novel ocular drug deliv-
ery system that not only increases the aqueous solubility of
TET but also overcomes the shortcomings of conventional
dosage forms. The purpose of this study was to design a
novel ocular delivery system to improve the ocular bio-
availability of TET. In this study, TET-loaded LCNPs
were prepared and investigated to determine their
physicochemical properties, including their entrapment
efficiency, drug loading capacity, drug utilization, zeta
potential, particle size, polydispersity index, particle
morphology, and crystalline lattice structure. In vitro
drug release from the LCNP system was determined
using a dynamic dialysis method. An in vitro penetra-
tion study was performed using freshly excised rabbit
corneas. Retention capacity was assessed using a nonin-
vasive fluorescence imaging system. Finally, in vivo
aqueous humor pharmacokinetics was investigated
using a microdialysis method.
Methods
Materials
GMO was purchased from Adamas Reagent Co., Ltd.
(Shanghai, China). Poloxamer 407 (F127) was obtained from
BASF (Ludwigshafen, Germany). Tetrandrine was purchased
from Jintai Biological Engineering Co., Ltd. (Shanxi, China).
Gelucire 44/14 was a gift of Gattefosse S.A. (Saint-Priest,
France). Amphipathic octadecyl-quaternized carboxymethyl
chitosan (QACMC) was supplied by Nantong Lushen
Biological Engineering Co., Ltd. (Jiangsu, China). All other
chemicals and reagents were of analytical grade.
Animals
New Zealand white rabbits weighing 2.5–3.0 kg were used
in the present study. The animals were housed at 25 ± 1 °C
in 50 ± 5 % relative humidity with access to food and water
ad libitum. All animal experiments were reviewed and ap-
proved by the Animal Ethical Committee at the Tianjin
University of Traditional Chinese Medicine.
Central Composite Factorial Design
During the preliminary study, the effect of each parameter
on the physicochemical properties of the TET-LCNPs was
assessed. To determine the optimal conditions for the
technical procedure, a total of 20 experimental runs were
performed according to the central composite design
principles using Design-Expert 8.06 (Stat Ease, Inc.,
Minneapolis, USA) as described in Table 1. A three-factor,
five-level central composite design was generated to
optimize the TET-LCNP preparation. The study design
involved investigating the effects of three independent
variables, including the amount of TET (X1), the amount
of GMO (X2), and the F127/GMO ratio (X3). The
dependent variables were the entrapment efficiency (Y1)
and drug loading capacity (Y2) of the TET-LCNPs.
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Preparation of TET-LCNPs
GMO, F127, and TET were dissolved in ethanol. The sub-
sequent evaporation of the solvent left the oil phase. The
QACMC and Gelucire 44/14 were dissolved in water to
form the water phase. Thereafter, the water phase was
dropped into the oil phase, and the mixture was
roughly mixed for 2 min at 75 °C using a high-shear
dispersing emulsifier (PRO200, PRO Scientific, USA).
A further reduction in size was achieved by treating
the mixture for 5 min (using a 5-s on and 5-s off
cycle) in an ultrasonic cell pulverizer (JYD-250L,
Zhixin Instruments Co., Ltd, China) at 200 W to ob-
tain a nanoemulsion.
Particle Size and Zeta Potential Analysis
The TET-LCNPs were diluted tenfold with water, and
their particle sizes, polydispersity indexes, and zeta poten-
tials were then determined at 25 °C using a Zetasizer
(Nano-ZS, Malvern Instruments Ltd., Worcestershire,
UK). All determinations were performed in triplicates.
Determination of Encapsulation Efficiency and Drug Loading
The drug encapsulation efficiency (EE) and drug loading
(DL) were determined using ultrafiltration in centrifuge
tubes that were fitted with an ultra-filter (Amicon Ultra,
MWCO 30 kDa, Millipore Company). About 500 μL of
each formulation was placed in the upper chamber, and
the tubes were then centrifuged at 5000 rpm for 30 min.
The amount of free drug in the filtrate was determined
at 283 nm using HPLC (LC20A, Shimadzu, Japan). The
mobile phase consisted of methanol/deionized water/
triethylamine (90:10:0.7, v/v/v) and was run at a flow rate
of 1.0 mL/min. TET was separated using a Dikma C18
column (5 μm, 4.6 × 250 mm). EE and DL were calcu-
lated using Eqs. 1 and 2
EE% ¼W total−W free
W total
 100 ð1Þ
DL% ¼ W total−W free
W total−W free þW lipid  100; ð2Þ
where Wtotal, Wfree, and Wlipid represent the total amount
of drug in the nanoparticles, the amount of drug in the
filtrate, and the amount of lipid in the formulation,
respectively.
Morphology
After diluting the samples 100-fold with purified
water, one drop of the LCNP suspension was depos-
ited onto a 300-mesh carbon-coated copper grid, and
the LCNPs were allowed to settle for 3–5 min. The
excess fluid was removed using absorbent paper, and
the samples were then visualized using a transmission
electron microscope (HT7700, Hitachi Ltd, Tokyo,
Japan).
Small-Angle X-Ray Scattering Measurement
Small-angle X-ray scattering (SAXS) measurements
were performed using a Xeuss 2.0 SAXS/WAXS sys-
tem (Xenocs, France) with pinhole collimation for
point focus geometry [18]. The SAXS camera was
equipped with a Hi-Star 2D detector. The optics and
sample chamber were used under vacuum conditions
to minimize air scatter. The liquid samples were
placed in 0.5-mm glass capillaries, and measurements
were performed in a vacuum at 25 °C with an expos-
ure time of 0.5 h.
In Vitro Drug Release Test
In vitro drug release was evaluated using the dynamic
dialysis bag method [19]. Briefly, 2 mL each of TET
solution and the TET-loaded LCNP formulation were
loaded separately into dialysis bags. The dialysis bags
were then immersed in 70 mL of freshly prepared
phosphate-buffered saline (PBS; pH 6.0) at 35 °C. The
magnetic stirring speed was 200 rpm. At predeter-
mined time intervals, 2 mL of each sample was with-
drawn and immediately replaced with an equal
volume of fresh PBS (pH 6.0). The concentration of
the drug that had been released by the particles was
determined using HPLC.
In Vitro Corneal Permeation Evaluation
Corneal permeation studies were performed using the
corneas that were excised from the rabbits [20]. The
rabbits were sacrificed with an injection of air into
the marginal ear vein. We then immediately excised
the corneas from the rabbits and preserved them in
glutathione bicarbonate Ringer’s solution (GBR). An
equal volume of each sample (500 μL) was added to
the donor chamber, and 4.5 mL of fresh PBS
(pH 6.0) was added to the receptor chamber. Samples
from the receptor chamber were withdrawn at prede-
termined time intervals and immediately replaced
with an equal volume of fresh PBS (pH 6.0). All
analyses were performed as described for the drug
Table 1 Independent variables and levels of experiment design
Independent variables Levels
−1.682 −1 0 1 1.682
X1: amount of TET (mg) 5 6.01 7.5 8.99 10
X2: amount of GMO (mg) 200 260.81 350 439.19 500
X3: F127/GMO (%) 9 10.22 12 13.78 15
A three-factor, five-level central composite design was generated to optimize
the TET-LCNP preparation. The study design involved investigating the effects
of three independent variables, including the amount of TET (X1), the amount
of GMO (X2), and the F127/GMO ratio (X3). The dependent variables were the
entrapment efficiency (Y1) and drug loading capacity (Y2) of the TET-LCNPs
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encapsulation efficiency evaluations. The experiments
were performed in triplicates. The apparent corneal
permeability coefficient (Papp) was calculated using




where ΔQΔt is the slope of the linear portion of the cumu-
lative permeated amount-versus-time plot, C0 is the ini-
tial drug concentration in the donor cell, A is the
exposed corneal surface area (0.5 cm2), and 60 was used
to convert minutes to seconds.
Pre-Ocular Retention Time Study
The pre-ocular retention of the TET-LCNP was assessed
using a noninvasive fluorescence imaging system (Night-
OWL II LB985, Berthold Technologies, Germany) [22].
The LCNP formulation was labeled as follows: TET was
replaced with rhodamine B (Rh B) in the oil phase, and
the formulation was then processed using the same
method that was used to prepare the LCNPs. The albino
rabbits were examined while conscious. Immediately be-
fore imaging, the animals were anesthetized using
chloral hydrate (injection 2.5 mL/kg) via the ear vein.
Precisely 20 μL of the formulation was injected directly
into the conjunctival sac of the right eye, and the left eye
was used as the control (Rh B solution). The eyes were
manually closed for 10 s to allow the solution to be dis-
tributed over the cornea. After 0, 0.17, 0.5, 1.0, 1.5, 2.0,
and 2.5 h, imaging was performed. The region of interest
(ROI) for the residual fluorescence was around the ocu-
lar and non-ocular areas. The remaining intensity (R)




where A was the intensity of ROI, B was the background
fluorescence intensity, and C was the intensity of the
ROI at 0 h [22].
Pharmacokinetic Study in Aqueous Humor
A pharmacokinetic study was performed on aqueous
humor fluids using microdialysis [23]. Briefly, three rab-
bits were locally anesthetized via an injection of 2.5 mL/
kg of chloral hydrate into the marginal ear vein. A mi-
crodialysis probe (MD 2000, Bioanalytical Systems, Inc.,
West Lafayette, IN) was implanted into the anterior
chamber of the eye using a 20-G needle. The needle was
then removed, leaving the probe with the microdialysis
membrane in the middle of the anterior chamber.
Thereafter, the probe was perfused with PBS (pH 6.0) at
a flow rate of 3 μL/min using a microdialysis pump
(CMA106, CMA Microdialysis Co., Ltd., Stockholm,
Sweden). The corneal wound surfaces were treated with
0.3 % (w/v) ofloxacin ophthalmic drops and allowed to
stabilize for 24 h before any agent was administered.
The dialysate was collected at 15 min after the 30 min
perfusion was completed. In vivo recovery (R) was calcu-




where Cd, Cp, and Cm are the concentrations of the drug
in the dialysate, perfusate, and aqueous humor, respect-
ively. R is the value of the slope of the plot of (Cd −Cp)
versus Cp.
Next, 0.2 mL of each formulation (1.0 mg/mL) was
injected into the eyes of separate groups of rabbits. Dial-
ysates were collected every 20 min for the first 2 h and
every 30 min thereafter after instillation. Each experi-
ment was repeated three times, and all samples were
analyzed using HPLC.
Statistical Analysis
The optimized TET-LCNPs and all data were analyzed
using Design-Expert software (8.06 version, Stat Ease,
Inc., Minneapolis, MN) [24]. The results are presented
as the mean ± standard deviation. Statistical analyses of
the results were performed using two-way analysis of
variance and one-way ANOVA in SPSS software (version
17.0, SPSS Inc., IL, USA). Statistical significance was
established at p < 0.05 [25].
Results and Discussion
Central Composite Factorial Design
A quadratic polynomial equation was used to determine
the responses according to differences in the independ-
ent variables, as shown in Eq. 6
Y ¼ A0 þ A1X1 þ A2X2 þ A3X3 þ A4X1X2
þ A5X2X3 þ A6X1X3 þ A7X12 þ A8X22
þ A9X32; ð6Þ
where Y is the dependent variable, X1–X3 are the inde-
pendent variables, and A1–A9 are the regression coeffi-
cients of the respective variables.
The best-fit model for the responses was the quadratic
model, which had the maximal r-value. The correlation
coefficient (r) was used as quality indicator to evaluate the
fitness of the second-order polynomial equation. ANOVA
was performed to evaluate the impact of the quadratic
model terms on response and quantitative effects, as
shown in Table 2. The respective p values shown in Table 2
indicate that the amount of TET (X1) and the amount of
GMO (X2) had significant effects (p < 0.05) on responses
but that the effect of the F127/GMO ratio (X3) was not
significant for EE and DL.
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The sign and value of the quantitative effect repre-
sented the tendencies and the magnitudes of the re-
sponses, respectively. EE and DL were the inputs used to
construct the respective response surface models
(RSMs). Response surface analyses were also plotted in
three-dimensional model graphs. The three-dimensional
response surface plots for EE and DL are presented in
Fig. 1. By analyzing these graphs, the optimal parameters
for the TET-LCNP formulation were found to be 10 mg
TET, 308.99 mg GMO with F127-to-GMO ratio of
12.99:100 (w/w), 0.1 % (w/v) Gelucire 44/14, 30 mg
QACMC, and 30 mL water. Table 3 shows the compari-
son between the actual and predicted data obtained from
the quadratic models. The proximity of the actual and
predicted values demonstrated the high validity and ad-
equacy of the model. This formulation was considered
to be the most appropriate formulation for ophthalmic
application, and it was therefore used for further
characterizations.
A central composite factorial design is a well-established
approach that is used in pharmaceutical formulation
development and optimization because it allows the
maximal amount of information to be extracted from
a small number of well-designed experiments. The
central composite design technique is a very useful
tool that provides statistical models, which help re-
searchers to understand the interactions between the
parameters that have been optimized and also helps
them to optimize the effective parameters using the
minimum number of experiments [26, 27]. This ap-
proach is therefore more efficient and economical
than using other designs [28].
Particle Size and Zeta Potential
Nanoparticle size has an important effect on the disper-
sion of ophthalmic formulations. The mean diameter of
the TET-LCNPs was 170.0 ± 13.34 nm, the mean polydis-
persity index was 0.166 ± 0.02 (Fig. 2a), and the distribu-
tion of particle sizes was relatively narrow. These
properties are advantageous for the uptake of TET-LCNPs
through the cornea. Many studies have attempted to
determine the optimal particle size for ophthalmic formu-
lations, and a narrow size range ensures a lower level of
irritation, adequate bioavailability, and good compatibility
with ocular tissues [29]. Sonication is a powerful approach
that can be used to decrease particle size, but one disad-
vantage of this technique is that strong mechanical treat-
ment can also degrade the lipid-water structure and
reduce drug loading capacity. The optimal formulation
had a positive surface charge of 29.3 ± 1.25 mV (Fig. 2b).
When the cationic material QACMC was added, the zeta
potential of the system was sufficiently high to provide
effective electric repulsion to avoid the aggregation of
particles [30]. Furthermore, F127 was used as a stabilizer,
and it also had a desirable effect in that it increased TET-
LCNPs stability [31].
Encapsulation Efficiency and Drug Loading
The EE was 95.46 ± 4.13 %, and the nanoparticles showed
1.63 ± 0.07 % DL, indicating that most of the drug was
encapsulated in the liquid crystalline nanoparticles.
Morphology of TET-LCNPs
When the samples were visualized using a transmission
electron microscope, spherically shaped particles with
smooth surfaces were observed, as shown in Fig. 3.
These findings indicated the successful formation of
TET-LCNPs.
SAXS Measurement
SAXS was performed to determine the structural
organization of the LCNP formulations. Several Bragg





: 2 [32], which indicates the inverted
hexagonal (H2) phase. Many studies have explored using
the dispersed L2 phase and V2 phase in ocular drug car-
riers [33]. However, only a small amount of evidence has
support the notion that the H2 phase can be a valuable
carrier for an ocular delivery system. In this study, in the
H2 phase, the amphiphilic molecules were organized as
nearly cylindrical aqueous tubes. This study has indi-
cated that the structure of the H2 phase, in terms of its
high internal interfacial area, is separated into hydro-
philic and hydrophobic domains. This finding suggests a
potential method for encapsulating hydrophilic, lipo-
philic, and amphiphilic drugs [34]. Because it possesses
Table 2 Regression coefficients of the quadratic equations in
optimization experiment
Parameters Regression coefficient
EE (%) p DL (%) p
A0 80.90 0.94
A1 3.33 <0.001 0.27 <0.001
A2 1.48 0.026 −0.09 <0.001
A3 −0.54 0.365 −1.07 × 10
−3 0.953
A4 0.22 0.770 5.00 × 10
−3 0.831
A5 0.22 0.899 −2.50 × 10
−3 0.299
A6 −0.10 0.775 −0.03 0.915
A7 1.70 0.012 0.06 0.009
A8 −1.46 0.024 −6.59 × 10
−3 0.706
A9 −0.61 0.293 0.01 0.529
r 92.85 98.26
p 0.0028 <0.0001
A0–A9 are the regression coefficients of the respective variables. The r-value
was used as a quality indicator to evaluate the fitness of the second-order
polynomial equation. The p value less than 0.05 was considered to be
statistically significant
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these properties, the H2 phase may be a promising can-
didate for TET delivery systems.
In Vitro Release of TET-LCNPs
The in vitro release profiles for the release of TET from
the TET solution and from the TET-LCNPs are
illustrated in Fig. 5. In this study, PBS (pH 6.0) was
selected to enhance the solubility of TET. TET rapidly
diffused from the TET solution, with approximately
53.60 % of the drug being released within 0.5 h. How-
ever, in the LCNP formulations, only 18.50 % of the drug
was released within the first 0.5 h, during which the
Fig. 1 RSM demonstrating the effect of the independent variables on EE and DL. X1 represents the amount of TET, X2 represents the amount of
GMO, and X3 represents the ratio between F127 and GMO. a Central composite design-response surface for the effect of the amount of TET (X1)
and the amount of GMO (X2) upon EE. b Central composite design-response surface for the effect of the amount of GMO (X2) and the F127/GMO
ratio (X3) upon EE. c Central composite design-response surface for the effect of the amount of TET (X1) and the F127/GMO ratio (X3) upon EE.
d Central composite design-response surface for the effect of the amount of TET (X1) and the F127/GMO ratio (X3) upon DL. e Central composite
design-response surface for the effect of the amount of TET (X1) and the amount of GMO (X2) upon DL. f Central composite design-response
surface for the effect of the amount of GMO (X2) and the F127/GMO ratio (X3) upon DL
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LCNPs exhibited an initial burst release of the drug. It is
clear that after the initial burst release from the LCNPs,
which lasted approximately 1.5 h, the rate of TET re-
lease from the LCNPs slowed and was close to the
Ritger-Peppas release (r = 0.9580). After 12 h, approxi-
mately 94.40 % of the TET had been released from the
LCNPs, while 99.00 % of the TET had been released
from the TET solution. The initial burst in the release of
the drug may have resulted from the release of free TET
that had adsorbed onto the nanoparticle surface.
Adsorbed TET would easily diffuse from the matrix, while
TET that had been incorporated into the nanoparticle
core would be released over a prolonged period [35]. Both
the initial burst release and the sustained-release portions
of the drug release profile are of interest for clinical appli-
cations. The initial burst is useful for improving drug
permeation and for pushing for a faster time of onset
for drug activity, while the sustained release of the
drug allows it to be administered over a more prolonged
period of time.
In Vitro Corneal Penetration Evaluation
A corneal penetration experiment was performed to
evaluate the ability of TET to penetrate across the cor-
nea when administered in either a TET solution or in a
solution of TET-LCNPs containing the same concentra-
tion TET. LCNPs considerably increased the ability of
TET to penetrate the cornea. The Papp values of the TET
solution and the TET-LCNPs were 1.23 × 10−5 and
2.50 × 10−5 cm/s, respectively. The Papp was 2.03-fold
higher for the TET-LCNPs than for the TET solution,
suggesting that more TET was taken up by the rabbit
corneas when TET-LCNPs were applied than when the
TET solution was applied. One potential reason that
LCNPs might enhance corneal permeation is the bioad-
hesive property of the liquid crystalline nanoparticles.
Fig. 2 Characteristics of TET-LCNPs. a Particle size distribution. b Zeta potential distribution. The TET-LCNPs were diluted tenfold with water; particle
size distribution and zeta potential were determined at 25 °C. All determinations were performed in triplicates
Table 3 Predicted values and actual values of optimal
prescription of TET-LCNPs
Parameter Predicted values (%) Actual values (%) Deviation (%)
EE 91.55 95.46 −4.27
DL 1.57 1.63 −3.82
Deviation (%) = (predicted values − actual values)/predicted values × 100 %
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Fig. 3 Photograph of TET-LCNPs taken using transmission electron micrograph. After diluting the samples 100-fold with purified water, one drop
of the LCNP suspension was deposited onto a 300-mesh carbon-coated copper grid, and the LCNPs were allowed to settle for 3–5 min. The excess
fluid was removed using absorbent paper, and the samples were then visualized using a transmission electron microscope
Fig. 4 SAXS profiles of the TET-LCNPs. The SAXS camera was equipped
with a Hi-Star 2D detector. The optics and sample chamber were used
under vacuum conditions to minimize air scatter. The liquid samples
were placed in 0.5-mm glass capillaries, and measurements were
performed in a vacuum at 25 °C with an exposure time of 0.5 h
Fig. 5 In vitro release profiles of TET released from a TET solution and
from TET-LCNPs (n= 3). In vitro drug release was evaluated using the
dynamic dialysis bag method. Two milliliters of each of TET solution and
the TET-loaded LCNP formulation was loaded separately into the dialysis
bags. The dialysis bags were then immersed in 70 mL of freshly prepared
phosphate-buffered saline (PBS, pH 6.0) at 35 °C. The magnetic stirring
speed was 200 rpm
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Their extremely small particle size and increased surface
area may promote the permeation of the drug. Another
potential reason is that the H2 phase, a promising candi-
date for drug delivery systems, may permit the incorpor-
ation of more drugs independent of drug solubility and
thereby improving drug permeation [36]. Moreover,
Gelucire 44/14 has been reported to be an effective en-
hancer of corneal permeation [37]. Thus, combining
LCNPs and Gelucire 44/14 might result in significantly
improved corneal penetration.
Pre-Ocular Retention of LCNPs
As shown in Fig. 6a, rapid drainage was observed in the
rhodamine B (Rh B) solution group following the admin-
istration of the drug. After 1.5 h, nearly no fluorescence
was observed in the ROI, and only a small amount of
fluorescence intensity remained in the lachrymal duct.
However, when the eyes were instilled with Rh B-
LCNPs, the diffusion of the drug was not as rapid in the
pre-corneal region, and relatively strong fluorescence
intensity was observed in the ROI for up to 1.5 h, as
shown in Fig. 6b.
Fluorescence intensity remaining in the ROI at 0.5 h
after administration was defined as A0.5. At 0.5 h, only
38.31 % fluorescence intensity remained in the ROI, which
was significantly lower than that of Rh B-LCNPs, A0.5 of
Rh B-LCNPs was 74.40 %, as displayed in Fig. 7. At 1.5 h,
the statistical analysis noted that 20.79 and 37.19 % inten-
sity remained in the Rh B solution and Rh B-LCNPs
group, respectively. A summary of statistical analysis is
shown in Table 4. The area under the concentration-time
curve (AUC) of the LCNP formulation was significantly
higher than that of solution (p < 0.01). There was about a
1.83-fold increase in AUC of Rh B-LCNPs compared to
that of Rh B solution. The clearance of Rh B-LCNPs in
the initial phase was much slower, as elimination rate
constant (Ke) was significantly lower than that of the Rh B
solution (p < 0.05). The Ke value for Rh B solution was
1.30-fold more than that obtained for the Rh B-LCNPs.
These results indicate that the application of the LCNP
formulation resulted in relatively strong fluorescence
intensity and slow clearance from the ROI. Adding the
cationic material QACMC increased the viscosity of the
aqueous phase, which hindered the rapid dispersion of the
particles from the corneal surface [38]. The addition of
positively charged QACMC resulted in electrostatic adhe-
sion or interactions with negatively charged mucin in the
corneal epithelium, which increased the ocular residence
time of the drug on the corneal surface [39]. Rh B as a
fluorescent dye was encapsulated in the nanoparticles,
which can reflect retention capacity of LCNPs [22]. Rh B
has many advantages as a fluorescent dye, such as cheap
and easy to get, good light stability, and high fluorescence
quantum yield [40].
Pharmacokinetic in Aqueous Humor
In vivo probe recovery was evaluated before the pharma-
cokinetic study to ensure that the implanted probes were
sufficiently functional. The in vivo recovery rate was
46.08 ± 1.93 % (n = 3).
The aqueous humor pharmacokinetics parameters are
summarized in Table 5. As shown in Fig. 8, the AUC value
was 2.65-fold higher for the TET-LCNPs than for the TET
solution (p < 0.01), and the peak concentration (Cmax) for
the TET-LCNPs was 2.08-fold higher (p < 0.01). The time
Fig. 6 Fluorescence images of rabbit eyes after administration of the
formulations. a Rh B solution and (b) Rh B-LCNPs. 1 ocular ROI, 2 intensity
reference standard, 3 inner canthus and nasolacrimal duct region
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to peak concentration (Tmax) and the half-time (t1/2) of
the TET-LCNPs were both longer than the same values
for the TET solution. The t1/2, Cmax, and AUC values for
the TET-LCNPs were significantly different from the
corresponding values for the TET solution (p < 0.01).
The enhanced ocular bioavailability that was provided
by the LCNP delivery system may result from three fac-
tors: the ocular contact time of the delivery system, the
ability of the drug to permeate through the cornea, and
a higher drug loading capacity. First, the pre-ocular
retention study indicated that the LCNP formulation re-
sulted in prolonged residence in the ROI, which may
have lengthened the ocular contact time. Second, our in
vitro study of corneal penetration showed that the Papp
of the LCNP formulations containing TET was 2.03-fold
higher than the Papp for the TET solution. Third, our re-
sults show that the H2 phase is a promising candidate
because it possesses specific structural properties, in-
cluding its high packing density and its extremely long
and straight water-filled rods, which can accommodate a
greater amount of the drug, resulting in improved drug
permeability through the cornea [41]. Furthermore,
Gelucire 44/14 enhances the absorption of poorly sol-
uble drugs, which contributes to improved drug bioavail-
ability. Together, these factors ensure intimate contact
between the drug and the epithelial mucosal surface of
the eye and prevent tear washout, and they are conse-
quently associated with a sustained drug release profile
and prolonged drug retention times. Using this drug
delivery system might be more advantageous than using
conventional dosage forms of TET because it is associ-
ated with increased solubility and bioavailability. It might
also improve patient compliance because of its sustained
effects and reduce the required dose, consequently
reducing any associated side effects.
Conclusions
In summary, the present study demonstrates the potential
of a TET-LCNP drug delivery system to increase drug
solubility and improve bioavailability. The optimal formu-
lation of TET-LCNPs was found to be nanosized and
uniformly dispersed. The in vitro results showed that
TET-LCNPs were associated with a more sustained re-
lease profile than those achieved using a TET solution.
The corneal penetration study revealed that LCNPs sig-
nificantly enhanced the transcorneal permeation of TET.
The enhancement of transcorneal permeation was further
supported by the results of an in vivo pharmacokinetics
study. The LCNP system is therefore a potential approach
for improving the ocular bioavailability of TET by enhan-
cing its ocular retention and corneal permeation.
Table 4 Pre-corneal clearance parameters (X  SD;n = 3)
Preparation AUC (% h) Ke (h
−1)
Rh B solution 73.83 ± 10.32 0.65 ± 0.06
Rh B-LCNPs 135.01 ± 17.07** 0.50 ± 0.01*
AUC area under the curve, Ke elimination rate constant
*p < 0.05 versus Rh B solution; **p < 0.01 versus Rh B solution
Fig. 8 TET concentration-time profiles when 200 μL was topically
administered at a dose of 1.0 mg/mL in the aqueous humor (n = 3)
Table 5 Pharmacokinetic parameters of TET in aqueous humor
after topical administration in the conscious rabbits (X  SD;n = 3)





TET solution 0.50 ± 0.10 0.41 ± 0.03 0.61 ± 0.03 0.85 ± 0.01
TET-LCNPs 0.83 ± 0.10* 0.86 ± 0.03** 1.64 ± 0.07** 1.41 ± 0.10**
Tmax time to peak concentration, Cmax maximal concentration of TET, AUC area
under the curve, t1/2 half-time
*p < 0.05 versus TET solution; **p < 0.01 versus TET solution
Fig. 7 Pre-ocular retention of various formulations (n = 3). Remaining
intensity (R) was calculated according to the equation: R = (A − B)/
C × 100 %, where A was the intensity of ROI, B was the background
fluorescence intensity, and C was the intensity of ROI at 0 min
Liu et al. Nanoscale Research Letters  (2016) 11:254 Page 10 of 12
Ethics Statement
New Zealand white rabbits (2.5–3.0 kg) were provided
by the Chinese Academy of Medical Sciences of
Radiation Research Institute (License No.: SCXK JIN
2013-0007). The animals, housed in standard cages in a
light-controlled room at 25 ± 1 °C and 50 ± 5 % relative
humidity, were fed with a standard pellet diet and water
ad libitum. Procedures involving animal care and man-
agement were reviewed and approved by the Animal
Ethical Committee at Tianjin University of Traditional
Chinese Medicine (document number TCM-LAEC
2014007).
Abbreviations
AUC: the area under the concentration-time curve; Cmax: concentration at
peak; DL: drug loading; EE: entrapment efficiency; F127: poloxamer 407;
GBR: glutathione bicarbonate Ringer’s solution; GMO: glyceryl monooleate;
Ke: elimination rate constant; LCNPs: liquid crystalline nanoparticle system;
Papp: the apparent corneal permeability coefficient; QACMC: amphipathic
octadecyl-quaternized carboxymethyl chitosan; R: recovery; Rh B: rhodamine
B; ROI: the region of interest; RSM: response surface model; SAXS: small-angle
X-ray scattering; t1/2: half-time; TET: tetrandrine; TET-LCNPs: TET-loaded
LCNPs; Tmax: the time to peak concentration.
Competing Interests
The authors declare that they have no competing interests.
Authors’ Contributions
RL, SW, and JW participated in the experimental design, performed the
experiments, and analyzed the data. SF, JC, XH, and CL assisted with data
analysis and in the writing of the paper. All of the authors have read and
approved the final manuscript.
Acknowledgements
This work was funded by the National Natural Science Foundation of China
(No. 81303142), the Specialized Research Fund for the Doctoral Program of
Higher Education of China (No. 20121210120001), the Tianjin Research Program
of Application Foundation and Advanced Technology (No. 14JCQNJC13100),
the National Science Foundation for Post-doctoral Researchers (No.
2015M570231), and the Program for Changjiang Scholars and Innovative
Research Team in University (No. IRT_14R41).
Author details
1School of Chinese Materia Medica, Tianjin University of Traditional Chinese
Medicine, 312 Anshanwest Road, Nankai District, Tianjin 300193, China.
2Tianjin State Key Laboratory of Modern Chinese Medicine, 312 Anshanwest
Road, Nankai District, Tianjin 300193, China. 3State Key Laboratory of Drug
Delivery Technology and Pharmacokinetics, Tianjin Institute of
Pharmaceutical Research, 308 Anshanwest Road, Nankai District, Tianjin
300193, China.
Received: 15 November 2015 Accepted: 6 May 2016
References
1. Ames P, Galor A (2015) Cyclosporine ophthalmic emulsions for the treatment
of dry eye: a review of the clinical evidence. Clin Investig (Lond) 5:267–285
2. Chetoni P, Monti D, Tampucci S, Matteoli B, Ceccherini-Nelli L, Subissi A et
al (2015) Liposomes as a potential ocular delivery system of distamycin A.
Int J Pharm 492:120–126. doi:10.1016/j.ijpharm.2015.05.055
3. Davaran S, Lotfipour F, Sedghipour N, Sedghipour MR, Alimohammadi S,
Salehi R (2015) Preparation and in vivo evaluation of in situ gel system as
dual thermo-/pH-responsive nanocarriers for sustained ocular drug delivery.
J Microencapsul 32:511–519. doi:10.3109/02652048.2015.1065915
4. Andrés-Guerrero V, Zong MM, Ramsay E, Rojas B, Sarkhel S, Gallego B et al
(2015) Novel biodegradable polyesteramide microspheres for controlled
drug delivery in ophthalmology. J Control Release 211:105–117.
doi:10.1016/j.jconrel.2015.05.279
5. Katzer T, Chaves P, Bernardi A, Pohlmann A, Guterres SS, Ruver Beck RC
(2014) Prednisolone-loaded nanocapsules as ocular drug delivery system:
development, in vitro drug release and eye toxicity. J Microencapsul 31:
519–528. doi:10.3109/02652048.2013.879930
6. Prosperi-Porta G, Kedzior S, Muirhead B, Sheardown H (2016) Phenylboronic-
acid-based polymeric micelles for mucoadhesive anterior segment ocular drug
delivery. Biomacromolecules 17:1449–1457. doi:10.1021/acs.biomac.6b0054
7. Avachat AM, Parpani SS (2015) Formulation and development of bicontinuous
nanostructured liquid crystalline particles of efavirenz. Colloids Surf B Biointerfaces
126:87–97. doi:10.1016/j.colsurfb.2014.12.014
8. Johnsson M, Barauskas J, Norlin A, Tiberg F (2006) Physicochemical and drug
delivery aspects of lipid-based liquid crystalline nanoparticles: a case study of
intravenously administered propofol. J Nanosci Nanotechnol 6:3017–3024
9. Esposito E, Cortesi R, Drechsler M, Paccamiccio L, Mariani P, Contado C
et al (2005) Cubosome dispersions as delivery systems for percutaneous
administration of indomethacin. Pharm Res 22:2163–2173
10. Chung H, Kim J, Um JY, Kwon IC, Jeong SY (2002) Self-assembled “nanocubicle”
as a carrier for peroral insulin delivery. Diabetologia 45:448–451
11. Bansal S, Kashyap CP, Aggarwal G, Harikumar SL (2012) A comparative
review on vesicular drug delivery system and stability issues. Int J Res
Pharm Chem 2:704–713
12. de Campo L, Yaghmur A, Sagalowicz L, Leser ME, Watzke H, Glatter O (2004)
Reversible phase transitions in emulsified nanostructured lipid systems.
Langmuir 20:5254–5261. doi:10.1021/la0499416
13. Yaghmur A, Glatter O (2009) Characterization and potential applications of
nanostructured aqueous dispersions. Adv Colloid Interface Sci 147–148:333–342.
doi:10.1016/j.cis.2008.07.007
14. Zeng N, Hu QY, Liu ZY, Gao XL, Hu RK, Song QX et al (2012) Preparation
and characterization of paclitaxel-loaded DSPE-PEG-liquid crystalline
nanoparticles (LCNPs) for improved bioavailability. Int J Pharm 424:58–66.
doi:10.1016/j.ijpharm.2011.12.058
15. Guo LJ, Zhang XF, Zhang S (2002) An experimental study of inhibition
of tetrandrine on posterior capsular opacification in rabbits. Zhonghua
Yan Ke za Zhi 38:235–238
16. Huang P, Xu YS, Wei RX, Li HP, Tang Y, Liu J et al (2011) Efficacy of tetrandrine
on lowering intraocular pressure in animal model with ocular hypertension.
J Glaucoma 20:183–188. doi:10.1097/IJG.0b013e3181d7882a
17. Liang XC, Hagino N, Guo SS, Tsutsumi T, Kobayashi S (2002) Therapeutic
efficacy of Stephania tetrandra S. Moore for treatment of neovascularization
of retinal capillary (retinopathy) in diabetes—in vitro study. Phytomedicine
9:377–384. doi:10.1078/09447110260571599
18. Li J, Wu L, Wu WJ, Wang BY, Wang ZY, Xin HL et al (2013) A potential carrier
based on liquid crystal nanoparticles for ophthalmic delivery of pilocarpine
nitrate. Int J Pharm 455:75–84. doi:10.1016/j.ijpharm.2013.07.057
19. Ezzati Nazhad Dolatabadi J, Hamishehkar H, Valizadeh H (2015) Development
of dry powder inhaler formulation loaded with alendronate solid lipid
nanoparticles: solid-state characterization and aerosol dispersion performance.
Drug Dev Ind Pharm 41:1431–1437. doi:10.3109/03639045.2014.956111
20. Hao JF, Wang XD, Bi YP, Teng YF, Wang JZ, Li F et al (2014) Fabrication of a
composite system combining solid lipid nanoparticles and thermosensitive
hydrogel for challenging ophthalmic drug delivery. Colloids Surf B Biointerfaces
114:111–120. doi:10.1016/j.colsurfb.2013.09.059
21. Muchtar S, Abdulrazik M, Frucht-Pery J, Benita S (1997) Ex-vivo permeation
study of indomethacin from a submicron emulsion through albino rabbit
cornea. J Control Release 44:55–64. doi:10.1016/S0168-3659(96)01503-9
22. Gan L, Han S, Shen JQ, Zhu JB, Zhu CL, Zhang XX et al (2010) Self-
assembled liquid crystalline nanoparticles as a novel ophthalmic delivery
system for dexamethasone: improving preocular retention and ocular
bioavailability. Int J Pharm 396:179–187. doi:10.1016/j.ijpharm.2010.06.015
23. Liu R, Liu ZD, Zhang CG, Zhang BL (2012) Nanostructured lipid carriers as
novel ophthalmic delivery system for mangiferin: improving in vivo ocular
bioavailability. J Pharm Sci 101:3833–3844. doi:10.1002/jps.23251
24. Verma S, Singh SK, Verma PRP, Ahsan MN (2014) Formulation by design of
felodipine loaded liquid and solid self nanoemulsifying drug delivery systems
using Box-Behnken design. Drug Dev Ind Pharm 40:1358–1370.
doi:10.3109/03639045.2013.819884
25. Varshosaz J, Minayian M, Moazen E (2010) Enhancement of oral bioavailability
of pentoxifylline by solid lipid nanoparticles. J Liposome Res 20:115–123.
doi:10.3109/08982100903161456
26. Hao JF, Wang FG, Wang XD, Zhang DR, Bi YP, Gao YS et al (2012) Development
and optimization of baicalin-loaded solid lipid nanoparticles prepared
Liu et al. Nanoscale Research Letters  (2016) 11:254 Page 11 of 12
by coacervation method using central composite design. Eur J Pharm
Sci 47:497–505. doi:10.1016/j.ejps.2012.07.006
27. Ranjan OP, Nayak UY, Reddy MS, Dengale SJ, Musmade PB, Udupa N (2014)
Optimization of chronomodulated delivery system coated with a blend of
ethyl cellulose and eudragit L100 by central composite design: in vitro and
in vivo evaluation. J Pharm Innov 9:95–105. doi:10.1007/s12247-014-9176-3
28. Wu J, Zhang H, Oturan N, Wang Y, Chen L, Oturan MA (2012) Application of
response surface methodology to the removal of the antibiotic tetracycline
by electrochemical process using carbon-felt cathode and DSA (Ti/RuO2-IrO2)
anode. Chemosphere 87:614–620. doi:10.1016/j.chemosphere.2012.01.036
29. Singh J, Chhabra G, Pathak K (2014) Development of acetazolamide-loaded,
pH-triggered polymeric nanoparticulate in situ gel for sustained ocular
delivery: in vitro. Ex vivo evaluation and pharmacodynamic study. Drug Dev
Ind Pharm 40:1223–1232. doi:10.3109/03639045.2013.814061
30. Levy MY, Schutze W, Fuhrer C, Benita S (1994) Characterization of diazepam
submicron emulsion interface: role of oleic acid. J Microencapsul 11:79–92.
doi:10.3109/02652049409040440
31. Luo Q, Lin TY, Zhang CY, Zhu TT, Wang L, Ji ZJ et al (2015) A novel glyceryl
monoolein-bearing cubosomes for gambogenic acid: preparation, cytotoxicity
and intracellular uptake. Int J Pharm 493:30–39. doi:10.1016/j.ijpharm.2015.07.036
32. Amar-Yuli I, Wachtel E, Shoshan EB, Danino D, Aserin A, Garti N (2007)
Hexosome and hexagonal phases mediated by hydration and polymeric
stabilizer. Langmuir 23:3637–3645. doi:10.1021/la062851b
33. Law SL, Huang KJ, Chiang CH (2000) Acyclovir-containing liposomes for
potential ocular delivery: corneal penetration and absorption. J Control
Release 63:135–140. doi:10.1016/S0168-3659(99)00192-3
34. Libster D, Ishai PB, Aserin A, Shoham G, Garti N (2009) Molecular interactions in
reverse hexagonal mesophase in the presence of cyclosporin A. Int J Pharm
367:115–126. doi:10.1016/j.ijpharm.2008.09.048
35. Zheng DD, Dai WT, Zhang DR, Duan CX, Jia LJ, Liu Y et al (2012) In vivo
studies on the oridonin-loaded nanostructured lipid carriers. Drug Deliv 19:
286–291. doi:10.3109/10717544.2012.704096
36. Achouri D, Sergent M, Tonetto A, Piccerelle P, Andrieu V, Hornebecq V
(2015) Self-assembled liquid crystalline nanoparticles as an ophthalmic
drug delivery system. Part II: optimization of formulation variables using
experimental design. Drug Dev Ind Pharm 41:493–501. doi:10.3109/
03639045.2014.884113
37. Liu R, Liu ZD, Zhang CG, Zhang BL (2011) Gelucire 44/14 as a novel absorption
enhancer for drugs with different hydrophilicities: in vitro and in vivo improvement
on transcorneal permeation. J Pharm Sci 100:3186–3195. doi:10.1002/jps.22540
38. Liu R, Sun L, Fang SM, Wang ST, Chen JJ, Xiao XF et al (2015) Thermosensitive
in situ nanogel as ophthalmic delivery system of curcumin: development,
characterization, in vitro permeation and in vivo pharmacokinetic studies.
Pharm Dev Technol 29:1–7. doi:10.3109/10837450.2015.1026607
39. Youshia J, Kamel AO, El Shamy A, Mansour S (2012) Design of cationic
nanostructured heterolipid matrices for ocular delivery of methazolamide.
Int J Nanomed 7:2483–2496. doi:10.2147/IJN.S28307
40. Karstens T, Kobs K (1980) Rhodamine B and rhodamine 101 as reference
substances for fluorescence quantum yield measurements. J Phys Chem 84:
1871–1872
41. Wu WJ, Li J, Wu L, Wang BY, Wang ZY, Xu QW et al (2013) Ophthalmic delivery
of brinzolamide by liquid crystalline nanoparticles: in vitro and in vivo evaluation.
AAPS PharmSciTech 14:1063–1071. doi:10.1208/s12249-013-9997-2
Submit your manuscript to a 
journal and beneﬁ t from:
7 Convenient online submission
7 Rigorous peer review
7 Immediate publication on acceptance
7 Open access: articles freely available online
7 High visibility within the ﬁ eld
7 Retaining the copyright to your article
    Submit your next manuscript at 7 springeropen.com
Liu et al. Nanoscale Research Letters  (2016) 11:254 Page 12 of 12
